個(gè)人簡(jiǎn)介:
中山大學(xué)附屬第七醫(yī)院—科研中心/泌尿外科副研究員,,碩士生導(dǎo)師。于2018年獲得中山大學(xué)-生物醫(yī)學(xué)材料學(xué)博士,,并于2019-2020在暨南大學(xué)-生物醫(yī)學(xué)工程進(jìn)行博士后研究工作,。2021年3月加入中山大學(xué)附屬第七醫(yī)院,,2024年4月晉升為副研究員。主持2項(xiàng)國(guó)家自然科學(xué)基金項(xiàng)目,、2項(xiàng)廣東省基金項(xiàng)目,、1項(xiàng)深圳市科創(chuàng)委-面上項(xiàng)目和1項(xiàng)中國(guó)博士后基金項(xiàng)目。共發(fā)表SCI論文30余篇和1篇專(zhuān)著,,研究成果主要發(fā)表在Nat Commun,、Sci Adv、ACS Nano,、Biomaterials,、Nano Today、Adv Sci,、Adv Funct Mater,、J Control Release、Acta Biomaterialia,、Nano Letter,、Small和ACS Appl. Mater. Interfaces等高水平期刊。其中第一或者通訊(含共同)SCI研究論文12篇,,SCI綜述論文2篇,。論文被引用1000余次,H index 15,。擔(dān)任Adv Mater,、Acta Biomaterialia、Adv Health Mater,、Biomater Res、Bioorganic Chem,、Small與Frontiers in Immunology等期刊審稿專(zhuān)家,。
?
教育背景:
2019-2020 暨南大學(xué) 生物醫(yī)學(xué)工程 博士后 合作導(dǎo)師:帥心濤教授&陳填峰教授
2013-2018 中山大學(xué) 生物醫(yī)學(xué)材料學(xué)/高分子化學(xué)與物理????直博 導(dǎo)師:帥心濤教授
2009-2013 中山大學(xué) 應(yīng)用化學(xué) ??學(xué)士
?
工作經(jīng)歷:
2024/04-至今 ???中山大學(xué)附屬第七醫(yī)院,,科研中心/泌尿外科,副研究員
2021/03-2024/03 中山大學(xué)附屬第七醫(yī)院,,特聘助理研究員
?
主要研究方向:
1. 前藥設(shè)計(jì),、合成和遞送:前體藥物的設(shè)計(jì)合成;發(fā)展生理微環(huán)境響應(yīng)的磷脂,、多肽和聚合物用于藥物(小分子,、基因和抗體等)的緩控釋放。
2. 生物活性高分子:采用可控聚合的方法開(kāi)發(fā)新型生物相容性的(輔助)治療型功能高分子(尤其是‘聚氨基酸’衍生物)及其在疾病治療中的應(yīng)用探索(例如抗腫瘤免疫治療),。
3. 再生醫(yī)學(xué):改性天然高分子,,結(jié)合藥物緩控釋技術(shù)和組織工程支架技術(shù),促組織修復(fù),。?
?
歡迎對(duì)此方向感興趣的本科生,、研究生和科研助理加入,共同探索生物醫(yī)學(xué)材料和生物有機(jī)合成技術(shù)及其在疾病治療中的應(yīng)用,。
?
發(fā)明專(zhuān)利(獲授權(quán))
1. 中國(guó)專(zhuān)利, 徐明; 黃金生; 郭煥玲; 張春陽(yáng); 帥心濤; 譚洋; 謝曉燕, 一種共同負(fù)載PD-L1抗體和STING激動(dòng)劑的納米囊泡及其制備方法與應(yīng)用,,專(zhuān)利號(hào):ZL202110769402.8。
2. 中國(guó)專(zhuān)利, 帥心濤; 黃金生; 徐永敏; 謝超; 程度, 一種用于腫瘤抗炎治療和化療的聚合物膠束及其制備方法,,專(zhuān)利號(hào):ZL201810555921.2,。
3. 中國(guó)專(zhuān)利, 帥心濤; 徐永敏; 黃金生; 程度, 一種輸送抗體用于腫瘤免疫治療的MR成像聚合物膠束及其制備方法,專(zhuān)利號(hào):ZL201710318845.9,。
4. 中國(guó)專(zhuān)利, 帥心濤; 萬(wàn)文清; 韓世松; 黃金生, 一種細(xì)胞核靶向的抗腫瘤納米藥物載體及其制備方和應(yīng)用,。專(zhuān)利號(hào):ZL201710564627.3。
?
經(jīng)費(fèi)項(xiàng)目
1. 微環(huán)境響應(yīng)的聚合物載體靶向高效遞送siRNA治療肝纖維化的研究,,2020.01-2022.12,,26萬(wàn)元,國(guó)家自然科學(xué)青年基金,,主持,。(已結(jié)題)
2. 生物醫(yī)用材料-納米醫(yī)學(xué),2021.03-2024.04,,30萬(wàn)元,,博士后留(來(lái))深科研資助,主持,。(在研)???????????????????????????
3. 雙重敏感的聚合物-磷酸鈣雜化納米膠囊用于RNAi誘導(dǎo)的氧化應(yīng)激和級(jí)聯(lián)化療,, 2022.01-2024.12,10萬(wàn)元,,廣東省自然科學(xué)基金面上項(xiàng)目,,主持。(在研)
4. 聚合物納米自噬抑制劑的研發(fā)及其增強(qiáng)前列腺癌免疫治療的研究,,2022.10-2025.10,,15萬(wàn)元,,深圳市科創(chuàng)委面上項(xiàng)目,主持,。(在研)
5. 非陽(yáng)離子聚合物載體用于mRNA遞送及其抗腫瘤研究,,2024.01-2027.12,50萬(wàn)元,,國(guó)家自然科學(xué)基金-面上項(xiàng)目,,主持。(在研)
6. 用于共載GSDME mRNA和化療藥物的非陽(yáng)離子聚合物載體研究,,2024-2026,,30萬(wàn)元,廣東省自然科學(xué)基金-青年提升項(xiàng)目,,主持,。(在研)
?
代表論文 (*為第一/共同第一作者,#為通訊/共同通訊作者):
1. Bin Xu#, Hanqi Lei#, Tongyu Tong#, Yupeng Guan, Yiyao Wang, Bo Li, Shiqiang Zhang, Xintao Shuai*, Jinsheng Huang* and Jun Pang*. Acidity-actuated polymer/calcium phosphate hybrid nanomotor (PCaPmotor) for penetrating drug delivery and synergistic anti-cancer immunotherapy. Nano Letter, 2024, (Revised, 共同通訊作者,,中科院1區(qū))
2. Keyu Chen#, Jiachen Wang#, Jue Cao#, Fei Liu, Weixin Zheng, Shubo Liu, Yuexin Zhao, Xintao Shuai*, Jinsheng Huang*, Bin Chen*. Enzyme-responsive microgel with controlled drug release, lubrication and adhesion capability for osteoarthritis attenuation. Acta Biomaterialia, 2024, (Revised, 共同通訊作者,,中科院1區(qū))
3. Bo Li#,*, Gengjia Chen#, Huihai Zhong, Tan Li, Minzhao Lin, Huiye Wei, Qiaoyun Zhang, Qiu Chen, Jinsheng Huang* and Xintao Shuai*. γ-Glutamyl transpeptidase-activable nanoprobe efficiently crosses the blood-brain barrier for immuno-sonodynamic therapy of glioma. Nat Commun, 2024, (Revised, 共同通訊作者,中科院1區(qū))
4. Bo Li #, *, Huihai Zhong#, Huiye Wei#, Gengjia Chen, Minzhao Lin, Sicong Huang, Qiaoyun Zhang, Chengfen Xing, Tan Li*, Jinsheng Huang*, Xintao Shuai*. Ultrasound-irradiated bindable microbomb opens the blood-brain barrier to enhance glioma therapy. Nano Today, 2024, 56, 102312. (共同通訊作者,,中科院1區(qū))
5. Yiyao Wang#, Hanqi Lei#, Binyuan Yan, Shiqiang Zhang, Bin Xu, Minzhao Lin, Xintao Shuai*, Jinsheng Huang*, and Jun Pang*. Tumor acidity-activatable macromolecule autophagy inhibitor and immune checkpoint blockage for robust treatment of prostate cancer. Acta Biomaterialia, 2023, 168, 593-605, DOI:10.1016/j.actbio.2023.07.018. (共同通訊作者,,中科院1區(qū))
6. Jinsheng Huang#, *, Huiling Huang#, Yiyao Wang#, Bin Xu, Minzhao Lin, Shisong Han, Yuanyuan Yuan*, Yong Wang*, Xintao Shuai*. Retinol-binding protein-hijacking nanopolyplex delivering siRNA to cytoplasm of hepatic stellate cell for liver fibrosis alleviation. Biomaterials, 2023, 299, 122134, DOI: 10.1016/j.biomaterials.2023.122134. (第一作者兼通訊作者,中科院1區(qū))
7. Xinghua Huang#, Jianwei Li#, Guanyi Li, Binyu Ni, Ziji Liang, Haodong Chen, Chaozhang Xu, Jianhua Zhou*, Jinsheng Huang*(共同通訊作者), and Shaohui Deng*. Cation-free siRNA-cored nanocapsules for tumor-targeted RNAi therapy, Acta Biomaterialia, 2023, 161, 226-237. DOI: 10.1016/j.actbio.2023.03.001. (共同通訊作者,,中科院1區(qū))
8. Yuanyuan Yuan, Yiyao Wang, Huiling Huang, Shuiliang Tao*, Jinsheng Huang*. Fine-Tuned Polymer Nanoassembly for Co-Delivery of Chemotherapeutic Drug and siRNA. Macromol. Biosci., 2023, 2200529. DOI: 10.1002/mabi.202200529. (最后通訊作者,,中科院3區(qū))
9. Huanling Guo#, Jinsheng Huang(共同一作)#, Yang Tan#, Wenxin Wu, Tongyi Huang, Nan Zhang, Shuling Chen, Chunyang Zhang*, Xiaoyan Xie*, Xintao Shuai*, Ming Xu*. Nanodrug shows spatiotemporally controlled release of anti-PDL1 antibody and STING agonist to effectively inhibit tumor progression after radiofrequency ablation. Nano Today, 2022, 43, 101425. DOI: 10.1016/j.nantod.2022.101425. (共同第一作者,中科院1區(qū))
10. Jinsheng Huang#, Chujie Zheng#, Hong Xiao#, Huiling Huang, Yiyao Wang, Minzhao Lin, Jun Pang YongWang, * YuanyuanYuan,* and Xintao Shuai*. A polymer?calcium phosphate nanocapsule for RNAi-induced oxidative stress and cascaded chemotherapy. J Control Release, 2021, 340, 259-270. DOI: 10.1016/j.jconrel.2021.10.030. (第一作者,,中科院1區(qū))
11. Jinsheng Huang#, Zecong Xiao#, Yongcheng An, Shisong, Han, Wei Wu, Yong Wang,* Yu Guo,* and Xintao Shuai*. Nanodrug with dual-sensitivity to tumor microenvironment for immuno-sonodynamic anti-cancer therapy. Biomaterials, 2021, 269, 120636. (第一作者,,中科院1區(qū))
12. Jinsheng Huang#, Yongmin Xu#, Hong Xiao, Zecong Xiao, Du Cheng, Yu Guo, Xintao Shuai*. Core-shell-distinct nanodrug showing on-demand sequential drug release to target multiple cell types for synergistic anticancer therapy. ACS Nano, 2019, 13(6), 7036-7049. (第一作者,中科院1區(qū))
13. Jun Wu#, Jinsheng Huang#, Sichi Kuang, Jingbiao Chen, Xiaoxia Li, Bin Chen, Jin Wang,* Du Cheng,* Xintao Shuai*.Synergistic microRNA therapy in liver fibrotic rat using MR-visible nanocarrier targeting hepatic stellate cells. Adv. Sci., 2019, 6(5), 1801809. (共同第一作者,,中科院1區(qū))
14. Jinsheng Huang#, Chaowen Lin#, Jintao Fang#, Xiaoxia Li, Jin Wang, Shaohui Deng, Sheng Zhang, Wanhan Su, Xiaoreng Feng, Bin Chen*, Du Cheng*, Xintao Shuai*. pH-sensitive nanocarrier-mediated codelivery of simvastatin and noggin siRNA for synergistic enhancement of osteogenesis. ACS Appl. Mater. Interfaces, 2018, 10, 28471-28482. (第一作者,,中科院2區(qū))
15. Yu Liu#, Wei Wu#, Yiyao Wang, Shisong Han, Yuanyuan Yuan, Jinsheng Huang,* Xintao Shuai* and Zhao Peng*. Recent development of gene therapy for pancreatic cancer using non-viral nanovectors. Biomater. Sci., 2021, 9, 6673-6690. DOI: 10.1039/d1bm00748c. (Review,共同通訊作者,,中科院2區(qū))
16. Mengjun Huang#, Qiliang Teng#, Fei Cao, Jinsheng Huang*, and Jun Pang*. Ferroptosis and ferroptosis-inducing nanomedicine as a promising weapon in combination therapy of prostate cancer. Biomater. Sci., 2024, 12, 1617-1629. DOI: 10.1039/D3BM01894F. (Review,,共同通訊作者,中科院2區(qū))
?
學(xué)術(shù)專(zhuān)著
個(gè)人郵箱: